Osaic Holdings
CNTA

Osaic Holdings’s Centessa Pharmaceuticals CNTA Stock Holding History

Osaic Holdings’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-407
Closed -$3.67K – 7424
2024
Q2 		$3.67K Buy
407
+107
+36% +$1.01K ﹤0.01% 6320
2024
Q1 		$3.39K Sell
300
-1,698
-85% -$16.1K ﹤0.01% 6259
2023
Q4 		$15.9K Sell
1,998
-815
-29% -$5.46K ﹤0.01% 5606
2023
Q3 		$18.2K Sell
2,813
-363
-11% -$2.48K ﹤0.01% 5608
2023
Q2 		$19.7K Buy
3,176
+431
+16% +$2.04K ﹤0.01% 5577
2023
Q1 		$10.6K Hold
2,745
– – ﹤0.01% 5946
2022
Q4 		$9K Buy
2,745
+860
+46% +$3.19K ﹤0.01% 5982
2022
Q3 		$7K Sell
1,885
-65
-3% -$297 ﹤0.01% 6174
2022
Q2 		$8K Buy
1,950
+935
+92% +$5.98K ﹤0.01% 6223
2022
Q1 		$9K Buy
1,015
+265
+35% +$2.42K ﹤0.01% 6196
2021
Q4 		$9K Buy
+750
New +$10.1K ﹤0.01% 6320

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Osaic Holdings's CNTA Position: Q3 2024 in Review

Osaic Holdings sold out of Centessa Pharmaceuticals (CNTA) in Q3 2024, closing a stake of 407 shares — an estimated $3.67K sold.

Osaic Holdings first reported a position in CNTA in Q4 2021 and held it in 11 quarters. The position peaked at $19.7K in Q2 2023. 103 funds tracked by Wall St. Rank hold CNTA as of Q3 2024.

  • Osaic Holdings reported no remaining Centessa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Osaic Holdings sold 407 Centessa Pharmaceuticals shares in Q3 2024, an estimated $3.67K.
  • Osaic Holdings first reported a position in Centessa Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • Osaic Holdings's Centessa Pharmaceuticals position peaked at $19.7K in Q2 2023.
  • 103 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2024.

Based on Osaic Holdings's 13F filing for Q3 2024, filed 13 Nov 2024.